Responses
Immunotherapy biomarkers
Original research
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
Compose a Response to This Article
Other responses
No responses have been published for this article.